Skip to main content
Fig. 1 | BMC Research Notes

Fig. 1

From: Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients

Fig. 1

The quantification of body composition using computed tomography (CT) scan at the level of third lumbar vertebra (L3). a, b Cross-sectional image at L3 level that measured the skeletal muscle mass and fat mass. c CT image before FOLFIRINOX chemotherapy. d CT image after 6 months of FOLFIRINOX chemotherapy. The purple color indicates skeletal muscle, yellow indicates visceral adipose tissue, and green indicates subcutaneous adipose tissue

Back to article page